Amyotrophic Lateral Sclerosis - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2027

October 2018 | 300 pages | ID: AAFB173542BEN
DelveInsight

Abstracts

This report can be delivered to the clients within 48 hours

'Amyotrophic Lateral Sclerosis - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2027', report provides comprehensive insights about marketed and pipeline drugs across this indication. The report covers an overview of the disease along with global historical and forecasted epidemiological data of Amyotrophic Lateral Sclerosis for the seven major markets i.e. United States, EU5 (France, Germany, Italy, Spain, UK) and Japan till 2027. Details about the current treatment practices and guidelines provided by the regulatory bodies of US and Europe. This report further provides comprehensive insights about the pipeline drugs. It covers all the clinical pipeline drug profiles and their comparative analysis. Furthermore, the report provides the detailed analysis of 70+ products along with 65+ companies involved.

Products covered by Phase

• Marketed Products
• Filed, Phase III, Phase II and Phase I
• Pre-clinical and Discovery

Overview of pipeline development activities for Amyotrophic Lateral Sclerosis

Pipeline analysis of 70+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.

Therapeutic segmentation of products for Amyotrophic Lateral Sclerosis

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.

METHODOLOGY

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SCOPE

• The report provides competitive pipeline landscape of Amyotrophic Lateral Sclerosis
• The report provides the marketed drugs information including its sales, development activities and details of patent expiry
• The report provides the insight of current and future market for Amyotrophic Lateral Sclerosis
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Amyotrophic Lateral Sclerosis and also provide company profiling
• Pipeline products coverage based on various stages of development ranging from late stage till discovery stage
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

REASONS TO BUY

• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
• Establish a comprehensive understanding of the current pipeline scenario Amyotrophic Lateral Sclerosis to formulate effective R&D strategies
• Assess challenges and opportunities that influence Amyotrophic Lateral Sclerosis R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of indication therapeutics
• Developing strategic initiatives to support your drug development activities
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Amyotrophic Lateral Sclerosis to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
• Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Contents

Executive Summary
Amyotrophic Lateral Sclerosis (ALS)
Disease Overview
Types
Stages
Causes
Pathophysiology
Symptoms
Risk Factors
Management of Amyotrophic Lateral Sclerosis
Diagnosis
Treatment
International Guidelines for the clinical management of Amyotrophic Lateral Sclerosis
Europe
United Kingdom
United States
Treatment Algorithm
Nutritional Treatment Algorithm
Respiratory Treatment Algorithm
Drug therapy Treatment Algorithm
Competitive Landscape
Designations
Marketed Products
Rilutek: Sanofi
Product Description
Research and Development
Product Development Activities
(The list continues)
Pipeline Therapeutics (Phase Products)
Pipeline Therapeutics (Early Phase Products)
Pipeline Therapeutics (Inactive Products)
Comparative Analysis
Late Stage Products (Filed and Phase III)
Comparative Analysis
Masitinib: AB Science
Product Description
Research and Development
Product Development Activities
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Therapeutic Assessment: Phase Products
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Pre-clinical and Discovery Products
Comparative Analysis
Dormant & Discontinued Products
Comparative Analysis
Key Findings on Epidemiology of ALS

7MM

Assumptions and Rationale
Incidence of ALS in 7MM
Incident Cases of ALS in 7MM
ALS Type Specific Incident Cases in 7MM
Age Specific Incidence of ALS in 7MM
Gender Specific Incidence of ALS in 7MM
Prevalence of ALS in 7MM
Prevalent Cases of ALS in 7MM
ALS Type Specific Prevalent Cases in 7MM
Age Specific Prevalence of ALS in 7MM
Gender Specific Prevalence of ALS in 7MM
United States
Assumptions and Rationale
Incident Cases of ALS in United States
ALS Type Specific Incident Cases in United States
Age Specific Incidence of ALS in United States
Gender Specific Incidence of ALS in United States
Race Specific Incidence of ALS in United States
Prevalent Cases of ALS in United States
ALS Type Specific Prevalent Cases in United States
Age Specific Prevalence of ALS in United States
Gender Specific Prevalence of ALS in United States
Race Specific Prevalence of ALS in United States
United Kingdom
Assumptions and Rationale
Incident Cases of ALS in United Kingdom
ALS Type Specific Incident Cases in United Kingdom
Age Specific Incidence of ALS in United Kingdom
Gender Specific Incidence of ALS in United Kingdom
Race Specific Incidence of ALS in United Kingdom
Prevalent Cases of ALS in United Kingdom
ALS Type Specific Prevalent Cases in United Kingdom
Age Specific Prevalence of ALS in United Kingdom
Gender Specific Prevalence of ALS in United Kingdom
Race Specific Prevalence of ALS in United Kingdom
France
Assumptions and Rationale
Incident Cases of ALS in France
ALS Type Specific Incident Cases in France
Age Specific Incidence of ALS in France
Gender Specific Incidence of ALS in France
Race Specific Incidence of ALS in France
Prevalent Cases of ALS in France
ALS Type Specific Prevalent Cases in France
Age Specific Prevalence of ALS in France
Gender Specific Prevalence of ALS in France
Race Specific Prevalence of ALS in France
Italy
Assumptions and Rationale
Incident Cases of ALS in Italy
ALS Type Specific Incident Cases in Italy
Age Specific Incidence of ALS in Italy
Gender Specific Incidence of ALS in Italy
Race Specific Incidence of ALS in Italy
Prevalent Cases of ALS in Italy
ALS Type Specific Prevalent Cases in Italy
Age Specific Prevalence of ALS in Italy
Gender Specific Prevalence of ALS in Italy
Race Specific Prevalence of ALS in Italy
Spain
Assumptions and Rationale
Incident Cases of ALS in Spain
ALS Type Specific Incident Cases in Spain
Age Specific Incidence of ALS in Spain
Gender Specific Incidence of ALS in Spain
Race Specific Incidence of ALS in Spain
Prevalent Cases of ALS in Spain
ALS Type Specific Prevalent Cases in Spain
Age Specific Prevalence of ALS in Spain
Gender Specific Prevalence of ALS in Spain
Race Specific Prevalence of ALS in Spain
Germany
Assumptions and Rationale
Incident Cases of ALS in Germany
ALS Type Specific Incident Cases in Germany
Age Specific Incidence of ALS in Germany
Gender Specific Incidence of ALS in Germany
Race Specific Incidence of ALS in Germany
Prevalent Cases of ALS in Germany
ALS Type Specific Prevalent Cases in Germany
Age Specific Prevalence of ALS in Germany
Gender Specific Prevalence of ALS in Germany
Race Specific Prevalence of ALS in Germany
Japan
Assumptions and Rationale
Incident Cases of ALS in Japan
ALS Type Specific Incident Cases in Japan
Age Specific Incidence of ALS in Japan
Gender Specific Incidence of ALS in Japan
Prevalent Cases of ALS in Japan
ALS Type Specific Prevalent Cases in Japan
Age Specific Prevalence of ALS in Japan
Gender Specific Prevalence of ALS in Japan
Global Epidemiology of ALS
Assumptions and Rationale
Global Incidence of ALS
Global Incident Cases of ALS
Global ALS Type Specific Incident Cases
Global Age Specific Incidence of ALS
Global Gender Specific Incidence of ALS
Global Prevalence of ALS
Global Prevalent Cases of ALS
Global ALS Type Specific Prevalent Cases
Global Age Specific Prevalence of ALS
Global Gender Specific Prevalence of ALS
Europe
Assumptions and Rationale
Incidence of ALS in EU5
Incident Cases of ALS in EU5
ALS Type Specific Incident Cases in EU5
Age Specific Incidence of ALS in EU5
Gender Specific Incidence of ALS in EU5
Race Specific Incidence of ALS in EU5
Prevalence of ALS in EU5
Prevalent Cases of ALS in EU5
ALS Type Specific Prevalent Cases in EU5
Age Specific Prevalence of ALS in EU5
Gender Specific Prevalence of ALS in EU5
RoW
Assumptions and Rationale
Incident Cases of ALS in RoW
ALS Type Specific Incident Cases in Spain
Age Specific Incidence of ALS in RoW
Gender Specific Incidence of ALS in RoW
Race Specific Incidence of ALS in RoW
Prevalent Cases of ALS in RoW
ALS Type Specific Prevalent Cases in Spain
Age Specific Prevalence of ALS in RoW
Gender Specific Prevalence of ALS in RoW
Market Outlook
United States Market Assessment
United States Market Size
United States: Market Share
Europe Market Assessment
Europe Market Size
Europe: Market Share
Japan Market Assessment
Japan Market Size
Japan: Market Share
RoW Market Assessment
RoW Market Size
RoW: Market Share
Global Market Assessment
Global Market Size
Global: Market Shares
Market Drivers and Barriers
Appendix

List Of Tables

LIST OF TABLES

Table 1: Drug Designations
Table 2: Total Products for Amyotrophic Lateral Sclerosis
Table 3: Late Stage Products (Filed and Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I)
Table 6: Assessment by Monotherapy Products
Table 7: Assessment by Combination Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Pre-clinical and Discovery Stage Products
Table 13: Dormant Products
Table 14: Discontinued Products
Table 15: 7MM, ALS Incident Cases, 2015-2027
Table 16: 7MM, ALS Type Specific Incident Cases, 2015-2027
Table 17: 7MM, Age Specific Incidence of ALS, 2015-2027
Table 18:7MM, Gender Specific Incidence of ALS, 2015-2027
Table 19: 7MM, ALS Prevalent Cases, 2015-2027
Table 20: 7MM, ALS Type Specific Prevalent Cases, 2015-2027
Table 21: 7MM, Age Specific Prevalence of ALS, 2015-2027
Table 22: 7MM, Gender Specific Prevalence of ALS, 2015-2027
Table 23: United States, ALS Incident Cases, 2015-2027
Table 24: United States, ALS Type Specific Incident Cases, 2015-2027
Table 25:United States, Age Specific Incidence of ALS, 2015-2027
Table 26: United States, Gender Specific Incidence of ALS, 2015-2027
Table 27: United States, Race Specific Incidence of ALS, 2015-2027
Table 28: United States, ALS Prevalent Cases, 2015-2027
Table 29: United States, ALS Type Specific Prevalent Cases, 2015-2027
Table 30: United States, Age Specific Prevalence of ALS, 2015-2027
Table 31: United States, Gender Specific Prevalence of ALS, 2015-2027
Table 32: United States, Race Specific Prevalence of ALS, 2015-2027
Table 33: United Kingdom, ALS Incident Cases, 2015-2027
Table 34: United Kingdom, ALS Type Specific Incident Cases, 2015-2027
Table 35: United Kingdom, Age Specific Incidence of ALS, 2015-2027
Table 36: United Kingdom, Gender Specific Incidence of ALS, 2015-2027
Table 37: United Kingdom, Race Specific Incidence of ALS, 2015-2027
Table 38: United Kingdom, ALS Prevalent Cases, 2015-2027
Table 39: United Kingdom, ALS Type Specific Prevalent Cases, 2015-2027
Table 40: United Kingdom, Age Specific Prevalence of ALS, 2015-2027
Table 41: United Kingdom, Gender Specific Prevalence of ALS, 2015-2027
Table 42: United Kingdom, Race Specific Prevalence of ALS, 2015-2027
Table 43: France, ALS Incident Cases, 2015-2027
Table 44: France, ALS Type Specific Incident Cases, 2015-2027
Table 45: France, Age Specific Incidence of ALS, 2015-2027
Table 46: France, Gender Specific Incidence of ALS, 2015-2027
Table 47: France, Race Specific Incidence of ALS, 2015-2027
Table 48: France, ALS Prevalent Cases, 2015-2027
Table 49: France, ALS Type Specific Prevalent Cases, 2015-2027
Table 50: France, Age Specific Prevalence of ALS, 2015-2027
Table 51: France, Gender Specific Prevalence of ALS, 2015-2027
Table 52: France, Race Specific Prevalence of ALS, 2015-2027
Table 53: Italy, ALS Incident Cases, 2015-2027
Table 54: Italy, ALS Type Specific Incident Cases, 2015-2027
Table 55: Italy, Age Specific Incidence of ALS, 2015-2027
Table 56: Italy, Gender Specific Incidence of ALS, 2015-2027
Table 57: Italy, Race Specific Incidence of ALS, 2015-2027
Table 58: Italy, ALS Prevalent Cases, 2015-2027
Table 59: Italy, ALS Type Specific Prevalent Cases, 2015-2027
Table 60: Italy, Age Specific Prevalence of ALS, 2015-2027
Table 61: Italy, Gender Specific Prevalence of ALS, 2015-2027
Table 62: Italy, Race Specific Prevalence of ALS, 2015-2027
Table 63: Spain, ALS Incident Cases, 2015-2027
Table 64: Spain, ALS Type Specific Incident Cases, 2015-2027
Table 65: Spain, Age Specific Incidence of ALS, 2015-2027
Table 66: Spain, Gender Specific Incidence of ALS, 2015-2027
Table 67: Spain, Race Specific Incidence of ALS, 2015-2027
Table 68: Spain, ALS Prevalent Cases, 2015-2027
Table 69: Spain, ALS Type Specific Prevalent Cases, 2015-2027
Table 70: Spain, Age Specific Prevalence of ALS, 2015-2027
Table 71: Spain, Gender Specific Prevalence of ALS, 2015-2027
Table 72: Spain, Race Specific Prevalence of ALS, 2015-2027
Table 73: Germany, ALS Incident Cases, 2015-2027
Table 74: Germany, ALS Type Specific Incident Cases, 2015-2027
Table 75: Germany, Age Specific Incidence of ALS, 2015-2027
Table 76: Germany, Gender Specific Incidence of ALS, 2015-2027
Table 77: Germany, Race Specific Incidence of ALS, 2015-2027
Table 78: Germany, ALS Prevalent Cases, 2015-2027
Table 79: Germany, ALS Type Specific Prevalent Cases, 2015-2027
Table 80: Germany, Age Specific Prevalence of ALS, 2015-2027
Table 81: Germany, Gender Specific Prevalence of ALS, 2015-2027
Table 82: Germany, Race Specific Prevalence of ALS, 2015-2027
Table 83: Japan, ALS Incident Cases, 2015-2027
Table 84: Japan, ALS Type Specific Incident Cases, 2015-2027
Table 85: Japan, Age Specific Incidence of ALS, 2015-2027
Table 86: Japan, Gender Specific Incidence of ALS, 2015-2027
Table 87: Japan, ALS Prevalent Cases, 2015-2027
Table 88: Japan, ALS Type Specific Prevalent Cases, 2015-2027
Table 89: Japan, Age Specific Prevalence of ALS, 2015-2027
Table 90: Japan, Gender Specific Prevalence of ALS, 2015-2027
Table 91: Global, ALS Incident Cases, 2015-2027
Table 92: Global, ALS Type Specific Incident Cases, 2015-2027
Table 93: Global, Age Specific Incidence of ALS, 2015-2027
Table 94: Global, Gender Specific Incidence of ALS, 2015-2027
Table 95: Global, ALS Prevalent Cases, 2015-2027
Table 96: Global, ALS Type Specific Prevalent Cases, 2015-2027
Table 97: Global, Age Specific Prevalence of ALS, 2015-2027
Table 98: Global, Gender Specific Prevalence of ALS, 2015-2027
Table 99: EU5, ALS Incident Cases, 2015-2027
Table 100: EU5, ALS Type Specific Incident Cases, 2015-2027
Table 101: EU5, Age Specific Incidence of ALS, 2015-2027
Table 102: EU5, Gender Specific Incidence of ALS, 2015-2027
Table 103: EU5, Race Specific Incidence of ALS, 2015-2027
Table 104: EU5, ALS Prevalent Cases, 2015-2027
Table 105: EU5, ALS Type Specific Prevalent Cases, 2015-2027
Table 106: EU5, Age Specific Prevalence of ALS, 2015-2027
Table 107: EU5, Gender Specific Prevalence of ALS, 2015-2027
Table 108: RoW, ALS Incident Cases, 2015-2027
Table 109: RoW, ALS Type Specific Incident Cases, 2015-2027
Table 110: RoW, Age Specific Incidence of ALS, 2015-2027
Table 111: RoW, Gender Specific Incidence of ALS, 2015-2027
Table 112: RoW, Race Specific Incidence of ALS, 2015-2027
Table 113: RoW, ALS Prevalent Cases, 2015-2027
Table 114: RoW, ALS Type Specific Prevalent Cases, 2015-2027
Table 115: RoW, Age Specific Prevalence of ALS, 2015-2027
Table 116:RoW, Gender Specific Prevalence of ALS, 2015-2027

List Of Figures

LIST OF FIGURES

Figure 1: Schematic representation of Amyotrophic Lateral Sclerosis
Figure 2: Pathophysiology of Amyotrophic Lateral Sclerosis
Figure 3: Drug Designations
Figure 4: Total Products for Amyotrophic Lateral Sclerosis
Figure 5: Late Stage Products (Filed and Phase III)
Figure 6: Mid Stage Products (Phase II)
Figure 7: Early Stage Products (Phase I)
Figure 8: Assessment by Monotherapy Products
Figure 9: Assessment by Route of Administration
Figure 10: Assessment by Stage and Route of Administration
Figure 11: Assessment by Molecule Type
Figure 12: Assessment by Stage and Molecule Type
Figure 13: Pre-clinical Stage and Discovery Products
Figure 14: Dormant & Discontinued Products
Figure 15: 7MM, ALS Incident Cases, 2015-2027
Figure 16: 7MM, ALS Type Specific Incident Cases, 2015-2027
Figure 17: 7MM, Age Specific Incidence of ALS, 2015-2027
Figure 18: 7MM, Gender Specific Incidence of ALS, 2015-2027
Figure 19:7MM, ALS Prevalent Cases, 2015-2027
Figure 20: 7MM, ALS Type Specific Prevalent Cases, 2015-2027
Figure 21: 7MM, Age Specific Prevalence of ALS, 2015-2027
Figure 22: 7MM, Gender Specific Prevalence of ALS, 2015-2027
Figure 23: United States, ALS Incident Cases, 2015-2027
Figure 24: United States, ALS Type Specific Incident Cases, 2015-2027
Figure 25:United States, Age Specific Incidence of ALS, 2015-2027
Figure 26: United States, Gender Specific Incidence of ALS, 2015-2027
Figure 27: United States, Race Specific Incidence of ALS, 2015-2027
Figure 28: United States, ALS Prevalent Cases, 2015-2027
Figure 29: United States, ALS Type Specific Prevalent Cases, 2015-2027
Figure 30: United States, Age Specific Prevalence of ALS, 2015-2027
Figure 31: United States, Gender Specific Prevalence of ALS, 2015-2027
Figure 32: United States, Race Specific Prevalence of ALS, 2015-2027
Figure 33: United Kingdom, ALS Incident Cases, 2015-2027
Figure 34: United Kingdom, ALS Type Specific Incident Cases, 2015-2027
Figure 35: United Kingdom, Age Specific Incidence of ALS, 2015-2027
Figure 36: United Kingdom, Gender Specific Incidence of ALS, 2015-2027
Figure 37: United Kingdom, Race Specific Incidence of ALS, 2015-2027
Figure 38: United Kingdom, ALS Prevalent Cases, 2015-2027
Figure 39: United Kingdom, ALS Type Specific Prevalent Cases, 2015-2027
Figure 40: United Kingdom, Age Specific Prevalence of ALS, 2015-2027
Figure 41: United Kingdom, Gender Specific Prevalence of ALS, 2015-2027
Figure 42: United Kingdom, Race Specific Prevalence of ALS, 2015-2027
Figure 43: France, ALS Incident Cases, 2015-2027
Figure 44: France, ALS Type Specific Incident Cases, 2015-2027
Figure 45: France, Age Specific Incidence of ALS, 2015-2027
Figure 46: France, Gender Specific Incidence of ALS, 2015-2027
Figure 47: France, Race Specific Incidence of ALS, 2015-2027
Figure 48: France, ALS Prevalent Cases, 2015-2027
Figure 49: France, ALS Type Specific Prevalent Cases, 2015-2027
Figure 50: France, Age Specific Prevalence of ALS, 2015-2027
Figure 51: France, Gender Specific Prevalence of ALS, 2015-2027
Figure 52: France, Race Specific Prevalence of ALS, 2015-2027
Figure 53: Italy, ALS Incident Cases, 2015-2027
Figure 54: Italy, ALS Type Specific Incident Cases, 2015-2027
Figure 55: Italy, Age Specific Incidence of ALS, 2015-2027
Figure 56: Italy, Gender Specific Incidence of ALS, 2015-2027
Figure 57: Italy, Race Specific Incidence of ALS, 2015-2027
Figure 58: Italy, ALS Prevalent Cases, 2015-2027
Figure 59: Italy, ALS Type Specific Prevalent Cases, 2015-2027
Figure 60: Italy, Age Specific Prevalence of ALS, 2015-2027
Figure 61: Italy, Gender Specific Prevalence of ALS, 2015-2027
Figure 62: Italy, Race Specific Prevalence of ALS, 2015-2027
Figure 63: Spain, ALS Incident Cases, 2015-2027
Figure 64: Spain, ALS Type Specific Incident Cases, 2015-2027
Figure 65: Spain, Age Specific Incidence of ALS, 2015-2027
Figure 66: Spain, Gender Specific Incidence of ALS, 2015-2027
Figure 67: Spain, Race Specific Incidence of ALS, 2015-2027
Figure 68: Spain, ALS Prevalent Cases, 2015-2027
Figure 69: Spain, ALS Type Specific Prevalent Cases, 2015-2027
Figure 70: Spain, Age Specific Prevalence of ALS, 2015-2027
Figure 71: Spain, Gender Specific Prevalence of ALS, 2015-2027
Figure 72: Spain, Race Specific Prevalence of ALS, 2015-2027
Figure 73: Germany, ALS Incident Cases, 2015-2027
Figure 74: Germany, ALS Type Specific Incident Cases, 2015-2027
Figure 75: Germany, Age Specific Incidence of ALS, 2015-2027
Figure 76: Germany, Gender Specific Incidence of ALS, 2015-2027
Figure 77: Germany, Race Specific Incidence of ALS, 2015-2027
Figure 78: Germany, ALS Prevalent Cases, 2015-2027
Figure 79: Germany, ALS Type Specific Prevalent Cases, 2015-2027
Figure 80: Germany, Age Specific Prevalence of ALS, 2015-2027
Figure 81: Germany, Gender Specific Prevalence of ALS, 2015-2027
Figure 82: Germany, Race Specific Prevalence of ALS, 2015-2027
Figure 83: Japan, ALS Incident Cases, 2015-2027
Figure 84: Japan, ALS Type Specific Incident Cases, 2015-2027
Figure 85: Japan, Age Specific Incidence of ALS, 2015-2027
Figure 86: Japan, Gender Specific Incidence of ALS, 2015-2027
Figure 87: Japan, ALS Prevalent Cases, 2015-2027
Figure 88: Japan, ALS Type Specific Prevalent Cases, 2015-2027
Figure 89: Japan, Age Specific Prevalence of ALS, 2015-2027
Figure 90: Japan, Gender Specific Prevalence of ALS, 2015-2027
Figure 91: Global, ALS Incident Cases, 2015-2027
Figure 92: Global, ALS Type Specific Incident Cases, 2015-2027
Figure 93: Global, Age Specific Incidence of ALS, 2015-2027
Figure 94: Global, Gender Specific Incidence of ALS, 2015-2027
Figure 95: Global, ALS Prevalent Cases, 2015-2027
Figure 96: Global, ALS Type Specific Prevalent Cases, 2015-2027
Figure 97: Global, Age Specific Prevalence of ALS, 2015-2027
Figure 98: Global, Gender Specific Prevalence of ALS, 2015-2027
Figure 99: EU5, ALS Incident Cases, 2015-2027
Figure 100: EU5, ALS Type Specific Incident Cases, 2015-2027
Figure 101: EU5, Age Specific Incidence of ALS, 2015-2027
Figure 102: EU5, Gender Specific Incidence of ALS, 2015-2027
Figure 103: EU5, Race Specific Incidence of ALS, 2015-2027
Figure 104: EU5, ALS Prevalent Cases, 2015-2027
Figure 105: EU5, ALS Type Specific Prevalent Cases, 2015-2027
Figure 106: EU5, Age Specific Prevalence of ALS, 2015-2027
Figure 107: EU5, Gender Specific Prevalence of ALS, 2015-2027
Figure 108: RoW, ALS Incident Cases, 2015-2027
Figure 109: RoW, ALS Type Specific Incident Cases, 2015-2027
Figure 110: RoW, Age Specific Incidence of ALS, 2015-2027
Figure 111: RoW, Gender Specific Incidence of ALS, 2015-2027
Figure 112: RoW, Race Specific Incidence of ALS, 2015-2027
Figure 113: RoW, ALS Prevalent Cases, 2015-2027
Figure 114: RoW, ALS Type Specific Prevalent Cases, 2015-2027
Figure 115: RoW, Age Specific Prevalence of ALS, 2015-2027
Figure 116: RoW, Gender Specific Prevalence of ALS, 2015-2027
Figure 117: United States Market Size
Figure 118: Europe Market Size
Figure 119: Japan Market Size
Figure 120: RoW Market Size
Figure 121: Global Market Size